The Boston Globe

Vertex’s CEO was an AI skeptic. But not anymore.

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...
BioSpace

Vertex’s New Products Dim as Analysts Eye Kidney Portfolio

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy. Vertex clocked 11% growth ...
PV Tech

Trinasolar advances TOPCon 2.0 era with global delivery of Vertex N i-TOPCon Ultra modules

Trinasolar has officially begun the large-scale global rollout of its TOPCon 2.0 modules, marking a new milestone in high-efficiency solar deployment. The first batch of 300MW Vertex N 650W series ...
Seeking Alpha

Vertex Pharma plunges as trial setback overshadows Q2 beat

Vertex Pharmaceuticals (NASDAQ:VRTX) shares plunged on Tuesday despite the company posting second-quarter revenue and adjusted profit above expectations. The stock is down 17% in early trade after the ...
Investopedia

Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
Seeking Alpha

Vertex Pharmaceuticals stock falls as pain drug fails in phase 2

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...
Wall Street Journal

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings

Vertex Pharmaceuticals’VRTX-0.02%decrease; red down pointing triangle stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into ...
Reuters

Vertex's trial failure, scrapped study cloud pain drug push; shares slump

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...
The Boston Globe

Vertex next-generation pain candidate fails Phase 2 trial

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex Pharmaceuticals said Monday that ...
Bloomberg L.P.

Vertex Falls After FDA Doubts Broad Use of Chronic Pain Drug

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...
STAT

Vertex next-generation pain candidate fails Phase 2 trial

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...